Personalized Solriamfetol Therapy for Impaired Renal Function

An optimized system for solriamfetol therapy in subjects with impaired renal function, providing personalized dosing, treatment outcome monitoring, and adaptive dose adjustment to minimize adverse effects.

The original patent disclosed methods for decreasing adverse effects associated with solriamfetol therapy in subjects with impaired renal function. However, it did not provide a comprehensive system for personalized dosing, treatment outcome monitoring, and adaptive dose adjustment. The new inventive concept addresses this limitation by introducing a system that integrates renal function assessment, dosing optimization, and treatment outcome monitoring to ensure safe and effective solriamfetol therapy.

The inventive concept comprises a system for personalized solriamfetol therapy, including a renal function assessment module, a dosing optimization module, and a treatment outcome monitoring module. The dosing optimization module adjusts the solriamfetol dose based on the subject's renal function and treatment outcome. The system can be implemented as a computer-implemented system, a pharmaceutical composition, or a method for reducing adverse effects associated with solriamfetol therapy. The system provides a recommended solriamfetol dose based on the subject's renal function and treatment outcome prediction, ensuring a reduced risk of adverse effects in subjects with moderate renal impairment.

The new inventive concept introduces a novel system for personalized solriamfetol therapy, which is not obvious from the original patent. The integration of renal function assessment, dosing optimization, and treatment outcome monitoring provides a non-obvious solution to the problem of adverse effects associated with solriamfetol therapy in subjects with impaired renal function.

Alternative embodiments of the inventive concept include the use of machine learning algorithms to predict treatment outcomes, the integration of wearable devices for real-time renal function monitoring, and the development of mobile applications for patient engagement and treatment adherence.

The inventive concept has significant commercial potential in the pharmaceutical industry, particularly in the treatment of excessive daytime sleepiness in subjects with impaired renal function. The system can be marketed as a comprehensive solution for personalized solriamfetol therapy, providing a competitive advantage in the market.